QuantuMDx announces approval of its Rapid Q-POC™ SARS-CoV-2 assay in the UK under CTDA legislation QuantuMDx announces approval of its Rapid Q-POCTM SARS-CoV-2 assay in the UK under CTDA legislation NEWCASTLE UPON TYNE, UK, 22 February 2022. QuantuMDx Group Limited (“QuantuMDx”), today announces...

QuantuMDx confirm its diagnostic tests remain able to detect all known variants of COVID-19 including the new variant from South Africa, B.1.1.529 NEWCASTLE UPON TYNE, UK, 26 NOVEMBER 2021. QuantuMDx Group Limited (“QuantuMDx”), today confirms that both its SARS-CoV-2 assays for open PCR platforms and its rapid PCR device, Q-POC™, as well as its...

QuantuMDx Group Ltd has announced plans to expand the potential of its Q-POC™ technology and develop a quality control analytics system for cell and gene therapies (“C&GT”s), to be evaluated by GlaxoSmithKline’s C&GT platform group. Press Release: 17 April 2019 QuantuMDx Group Ltd has announced plans to expand the potential of its Q-POC™ technology and develop a quality control analytics system for cell and gene therapies...